JS 005
Alternative Names: JS-005Latest Information Update: 19 Dec 2024
Price :
$50 *
At a glance
- Originator Shanghai Junshi Biosciences
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Monoclonal antibodies
- Mechanism of Action IL17A protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Plaque psoriasis
- Phase II Ankylosing spondylitis; Axial spondyloarthritis; Psoriatic arthritis
Most Recent Events
- 19 Dec 2024 Shanghai Junshi Biosciences plans a phase I bioequivalence trial (In volunteers) in China (SC), in December 2024 (NCT06732973)
- 12 Jan 2024 Phase-II clinical trials in Ankylosing spondylitis in China (SC) (NCT06250062)
- 10 Nov 2023 Interim efficacy and adverse events data from a phase I/II trial in plaque psoriasis presented at the ACR Convergence 2023 (ACR-2023)